Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budoprutug in Systemic Lupus Erythematosus
NCT07564596Phase 2Recruiting
- Sponsor
- Climb Bio
- Start
- Jun 2026
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of budoprutug in systemic lupus erythematosus (SLE), sponsored by Climb Bio. Started Jun 2026; status: recruiting.
02
Drugs
budoprutug
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07564596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07564596.